Branching Beyond Axonal Guidance and Into Immunity Ramon Garcia
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse
Welcome to More Choice CD Marker Handbook For more information, please visit: Human bdbiosciences.com/eu/go/humancdmarkers Mouse bdbiosciences.com/eu/go/mousecdmarkers Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse CD3 CD3 CD (cluster of differentiation) molecules are cell surface markers T Cell CD4 CD4 useful for the identification and characterization of leukocytes. The CD CD8 CD8 nomenclature was developed and is maintained through the HLDA (Human Leukocyte Differentiation Antigens) workshop started in 1982. CD45R/B220 CD19 CD19 The goal is to provide standardization of monoclonal antibodies to B Cell CD20 CD22 (B cell activation marker) human antigens across laboratories. To characterize or “workshop” the antibodies, multiple laboratories carry out blind analyses of antibodies. These results independently validate antibody specificity. CD11c CD11c Dendritic Cell CD123 CD123 While the CD nomenclature has been developed for use with human antigens, it is applied to corresponding mouse antigens as well as antigens from other species. However, the mouse and other species NK Cell CD56 CD335 (NKp46) antibodies are not tested by HLDA. Human CD markers were reviewed by the HLDA. New CD markers Stem Cell/ CD34 CD34 were established at the HLDA9 meeting held in Barcelona in 2010. For Precursor hematopoetic stem cell only hematopoetic stem cell only additional information and CD markers please visit www.hcdm.org. Macrophage/ CD14 CD11b/ Mac-1 Monocyte CD33 Ly-71 (F4/80) CD66b Granulocyte CD66b Gr-1/Ly6G Ly6C CD41 CD41 CD61 (Integrin b3) CD61 Platelet CD9 CD62 CD62P (activated platelets) CD235a CD235a Erythrocyte Ter-119 CD146 MECA-32 CD106 CD146 Endothelial Cell CD31 CD62E (activated endothelial cells) Epithelial Cell CD236 CD326 (EPCAM1) For Research Use Only. -
Atypical Functions of Leukocyte Chemoattractant Receptors
EDITORIAL published: 09 October 2020 doi: 10.3389/fimmu.2020.596902 Editorial: Atypical Functions of Leukocyte Chemoattractant Receptors José Luis Rodríguez-Fernández 1*, Mario Mellado 2*, Marcus Thelen 3* and Philip M. Murphy 4* 1 Department of Molecular Cell Biology, Centro de Investigaciones Biológicas Margarita Salas, Consejo Superior de Investigaciones Científicas, Madrid, Spain, 2 Department of Immunology and Oncology, Centro Nacional de Biotecnología, Consejo Superior de Investigaciones Científicas, Madrid, Spain, 3 Faculty of Biomedical Sciences, Institute for Research in Biomedicine, Università della Svizzera Italiana, Bellinzona, Switzerland, 4 Laboratory of Molecular Immunology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States Keywords: chemotaxis, chemokine, atypical chemokine receptor, G protein-coupled receptor, signaling, arrestin, GPCR Edited and reviewed by: Silvano Sozzani, Sapienza University of Rome, Italy Editorial on the Research Topic *Correspondence: José Luis Rodríguez-Fernández Atypical Functions of Leukocyte Chemoattractant Receptors [email protected] Mario Mellado Chemoattraction is a process that involves directed cell movement toward extracellular chemical [email protected] stimuli. It is a fundamental feature of all biological systems that was discovered in the late Marcus Thelen nineteenth century, when the word “chemotaxis” was coined by the German biologist Wilhelm [email protected] Pfeffer. Metchnikoff’s 1882 description of macrophages -
Stromal Cell–Derived Factor-1/CXCL12 Stimulates Chemorepulsion of NOD/Ltj T-Cell Adhesion to Islet Microvascular Endothelium Christopher D
ORIGINAL ARTICLE Stromal Cell–Derived Factor-1/CXCL12 Stimulates Chemorepulsion of NOD/LtJ T-Cell Adhesion to Islet Microvascular Endothelium Christopher D. Sharp,1 Meng Huang,1 John Glawe,1 D. Ross Patrick,1 Sible Pardue,1 Shayne C. Barlow,2 and Christopher G. Kevil1 OBJECTIVE—Diabetogenic T-cell recruitment into pancreatic islets faciltates -cell destruction during autoimmune diabetes, yet specific mechanisms governing this process are poorly un- iabetogenic T-cell infiltration into pancreatic derstood. The chemokine stromal cell–derived factor-1 (SDF-1) islets is a key pathophysiological feature of controls T-cell recruitment, and genetic polymorphisms of SDF-1 autoimmune diabetes. Recruitment of autoreac- are associated with early development of type 1 diabetes. tive T-cells into islets, known as insulitis, ini- D  tiates the process of -cell damage, which may occur over RESEARCH DESIGN AND METHODS—Here, we examined a protracted period of time, eventually leading to frank the role of SDF-1 regulation of diabetogenic T-cell adhesion to  islet microvascular endothelium. Islet microvascular endothelial destruction of -cells and loss of insulin production (1,2). cell monolayers were activated with tumor necrosis factor-␣ Cellular and molecular mechanisms necessary for recruit- (TNF-␣), subsequently coated with varying concentrations of ment and homing of diabetogenic T-cells have been pur- SDF-1 (1–100 ng/ml), and assayed for T-cell/endothelial cell posed, with antigen presentation and changes in adhesion interactions under physiological flow conditions. molecule expression playing important roles in this pro- cess (3–6). However, T-cell recruitment is regulated by RESULTS—TNF-␣ significantly increased NOD/LtJ T-cell adhe- other factors besides antigen presentation and adhesion sion, which was completely blocked by SDF-1 in a dose-depen- molecule expression. -
Immuno 2014 No. 1
Journal of Blood Group Serology and Molecular Genetics VOLUME 30, N UMBER 1, 2014 Immunohematology Journal of Blood Group Serology and Molecular Genetics Volume 30, Number 1, 2014 CONTENTS R EPORT 1 Indirect antiglobulin test-crossmatch using low-ionic-strength saline–albumin enhancement medium and reduced incubation time: effectiveness in the detection of most clinically significant antibodies and impact on blood utilization C.L. Dinardo, S.L. Bonifácio, and A. Mendrone, Jr. R EV I EW 6 Raph blood group system M. Hayes R EPORT 11 I-int phenotype among three individuals of a Parsi community from Mumbai, India S.R. Joshi C A SE R EPORT 14 Evans syndrome in a pediatric liver transplant recipient with an autoantibody with apparent specificity for the KEL4 (Kpb) antigen S.A. Koepsell, K. Burright-Hittner, and J.D. Landmark R EV I EW 18 JMH blood group system: a review S.T. Johnson R EPORT 24 Demonstration of IgG subclass (IgG1 and IgG3) in patients with positive direct antiglobulin tests A. Singh, A. Solanki, and R. Chaudhary I N M EMOR ia M 28 George Garratty, 1935–2014 Patricia A. Arndt and Regina M. Leger 30 A NNOUNCEMENTS 34 A DVERT I SEMENTS 39 I NSTRUCT I ONS FOR A UTHORS E D I TOR - I N -C H I EF E D I TOR ia L B OA RD Sandra Nance, MS, MT(ASCP)SBB Philadelphia, Pennsylvania Patricia Arndt, MT(ASCP)SBB Paul M. Ness, MD Pomona, California Baltimore, Maryland M A N AG I NG E D I TOR James P. -
Important Information for Female Platelet Donors
Important Information for Female Platelet Donors We are grateful for the support you provide our community blood program and especially appreciate your willingness to help save lives as a volunteer platelet donor. We also take our responsibility to provide a safe and adequate blood supply very seriously and need to share the following information regarding a change to our donor eligibility criteria for female platelet donors. We recently began performing a Human Leukocyte Antigen (HLA) antibody test on each of our current female platelet donors who have ever been pregnant. In addition, we modified our Medical History Questionnaire to ask donors whether they have been pregnant since their last donation. Platelet donors who respond yes to that question will be screened for HLA antibodies. Platelet donors will also be retested after every subsequent pregnancy. These adjustments are being made as part of our effort to reduce occurrences of Transfusion-Related Acute Lung Injury (TRALI). TRALI is a rare but serious complication of blood transfusions most commonly thought to be caused by a reaction to HLA antibodies present in the donor’s plasma. When transfused, these antibodies can sometimes cause plasma to leak into the patient’s lungs, creating fluid accumulation — a condition referred to as acute pulmonary edema. Female donors who have been pregnant are more likely than others to have these HLA antibodies in their plasma. Once the antibodies develop, they are present forever. The antibodies could be harmful if transfused into certain patients. The antibodies are present in plasma — and platelet donations contain a high volume of plasma, so our current efforts are directed at screening blood samples from female platelet donors to test for the HLA antibody. -
CD59: a Long-Known Complement Inhibitor Has Advanced to a Blood Group System
B LOOD G ROUP R EVIEW CD59: A long-known complement inhibitor has advanced to a blood group system C. Weinstock, M. Anliker, and I. von Zabern The blood group system number 35 is based on CD59, a 20-kDa by Zalman et al.1 from the group of H.J. Muller-Eberhard in La membrane glycoprotein present on a large number of different Jolla, California, and in 1988 by Schönermark et al. from the cells, including erythrocytes. The major function of CD59 is to group of G.M. Hänsch in Heidelberg (Germany).2 This inhibitor protect cells from complement attack. CD59 binds to complement components C8 and C9 and prevents the polymerization of C9, was published under the designations “HRF (homologous which is required for the formation of the membrane attack restriction factor)” and “C8bp (C8 binding protein),” complex (MAC). Other functions of CD59 in cellular immunity respectively, to describe its properties.1,2 “C8bp” indicates the are less well defined. CD59 is inserted into the membrane by a glycosylphosphatidylinositol (GPI) anchor. A defect of this anchor binding capacity for C8. The name “HRF” points to a species causes lack of this protein from the cell membrane, which leads to incompatibility of this “factor” that provides protection from an enhanced sensitivity towards complement attack. Patients with complement attack more effectively in a homologous (e.g., paroxysmal nocturnal hemoglobinuria (PNH) harbor a varying human erythrocytes as a target of human complement) than in percentage of red blood cell clones with a defect in GPI-anchored proteins, including CD59. The most characteristic symptoms of a heterologous system (e.g., human erythrocytes as a target of this disease are episodes of hemolysis and thromboses. -
Dendritic Cell Migration Semaphorin 7A Promotes Chemokine-Driven
Semaphorin 7A Promotes Chemokine-Driven Dendritic Cell Migration Anoek van Rijn, Leonie Paulis, Joost te Riet, Angela Vasaturo, Inge Reinieren-Beeren, Alie van der Schaaf, This information is current as Arthur J. Kuipers, Luuk P. Schulte, Bart C. Jongbloets, R. of September 28, 2021. Jeroen Pasterkamp, Carl G. Figdor, Annemiek B. van Spriel and Sonja I. Buschow J Immunol 2016; 196:459-468; Prepublished online 23 November 2015; Downloaded from doi: 10.4049/jimmunol.1403096 http://www.jimmunol.org/content/196/1/459 Supplementary http://www.jimmunol.org/content/suppl/2015/11/21/jimmunol.140309 http://www.jimmunol.org/ Material 6.DCSupplemental References This article cites 41 articles, 14 of which you can access for free at: http://www.jimmunol.org/content/196/1/459.full#ref-list-1 Why The JI? Submit online. by guest on September 28, 2021 • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2015 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. -
Multiomics of Azacitidine-Treated AML Cells Reveals Variable And
Multiomics of azacitidine-treated AML cells reveals variable and convergent targets that remodel the cell-surface proteome Kevin K. Leunga, Aaron Nguyenb, Tao Shic, Lin Tangc, Xiaochun Nid, Laure Escoubetc, Kyle J. MacBethb, Jorge DiMartinob, and James A. Wellsa,1 aDepartment of Pharmaceutical Chemistry, University of California, San Francisco, CA 94143; bEpigenetics Thematic Center of Excellence, Celgene Corporation, San Francisco, CA 94158; cDepartment of Informatics and Predictive Sciences, Celgene Corporation, San Diego, CA 92121; and dDepartment of Informatics and Predictive Sciences, Celgene Corporation, Cambridge, MA 02140 Contributed by James A. Wells, November 19, 2018 (sent for review August 23, 2018; reviewed by Rebekah Gundry, Neil L. Kelleher, and Bernd Wollscheid) Myelodysplastic syndromes (MDS) and acute myeloid leukemia of DNA methyltransferases, leading to loss of methylation in (AML) are diseases of abnormal hematopoietic differentiation newly synthesized DNA (10, 11). It was recently shown that AZA with aberrant epigenetic alterations. Azacitidine (AZA) is a DNA treatment of cervical (12, 13) and colorectal (14) cancer cells methyltransferase inhibitor widely used to treat MDS and AML, can induce interferon responses through reactivation of endoge- yet the impact of AZA on the cell-surface proteome has not been nous retroviruses. This phenomenon, termed viral mimicry, is defined. To identify potential therapeutic targets for use in com- thought to induce antitumor effects by activating and engaging bination with AZA in AML patients, we investigated the effects the immune system. of AZA treatment on four AML cell lines representing different Although AZA treatment has demonstrated clinical benefit in stages of differentiation. The effect of AZA treatment on these AML patients, additional therapeutic options are needed (8, 9). -
Immunotherapy in the Treatment of Human Solid Tumors: Basic and Translational Aspects
Journal of Immunology Research Immunotherapy in the Treatment of Human Solid Tumors: Basic and Translational Aspects Guest Editors: Roberta Castriconi, Barbara Savoldo, Daniel Olive, and Fabio Pastorino Immunotherapy in the Treatment of Human Solid Tumors: Basic and Translational Aspects Journal of Immunology Research Immunotherapy in the Treatment of Human Solid Tumors: Basic and Translational Aspects Guest Editors: Roberta Castriconi, Barbara Savoldo, Daniel Olive, and Fabio Pastorino Copyright © 2016 Hindawi Publishing Corporation. All rights reserved. This is a special issue published in “Journal of Immunology Research.” All articles are open access articles distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Editorial Board B. D. Akanmori, Congo Eung-Jun Im, USA G. Opdenakker, Belgium Stuart Berzins, Australia Hidetoshi Inoko, Japan Luigina Romani, Italy Kurt Blaser, Switzerland Peirong Jiao, China Aurelia Rughetti, Italy Federico Bussolino, Italy Taro Kawai, Japan Takami Sato, USA N. G. Chakraborty, USA Hiroshi Kiyono, Japan Senthamil Selvan, USA Robert B. Clark, USA Shigeo Koido, Japan Naohiro Seo, Japan Mario Clerici, Italy Herbert K. Lyerly, USA Ethan M. Shevach, USA Nathalie Cools, Belgium Enrico Maggi, Italy George B. Stefano, USA Mark J. Dobrzanski, USA Mahboobeh Mahdavinia, USA T. J. Stewart, Australia Nejat K. Egilmez, USA Eiji Matsuura, Japan J. Tabarkiewicz, Poland Eyad Elkord, UK C. J. M. Melief, The Netherlands Ban-Hock Toh, Australia S. E. Finkelstein, USA Chikao Morimoto, Japan Joseph F. Urban, USA Luca Gattinoni, USA Hiroshi Nakajima, Japan Xiao-Feng Yang, USA David E. Gilham, UK Toshinori Nakayama, Japan Qiang Zhang, USA Douglas C. -
1,25-Dihydroxyvitamin D3-Induced Genes in Osteoblasts
1,25-DIHYDROXYVITAMIN D3-INDUCED GENES IN OSTEOBLASTS: UNCOVERING NEW FUNCTIONS FOR MENINGIOMA 1 AND SEMAPHORIN 3B IN SKELETAL PHYSIOLOGY by XIAOXUE ZHANG Submitted in partial fulfillment of the requirements for the Degree of Doctor of Philosophy Thesis advisor: Paul N. MacDonald Department of Pharmacology CASE WESTERN RESERVE UNIVERSITY May 2009 CASE WESTERN RESERVE UNIVERSITY SCHOOL OF GRADUATE STUDIES We hereby approve the thesis/dissertation of _____________________________________________________ candidate for the ______________________degree *. (signed)_______________________________________________ (chair of the committee) ________________________________________________ ________________________________________________ ________________________________________________ ________________________________________________ ________________________________________________ (date) _______________________ *We also certify that written approval has been obtained for any proprietary material contained therein. I dedicate this thesis to my mother and father for their lifelong love, encouragement and sacrifice TABLE OF CONTENTS Table of Contents ii List of Tables iii List of Figures iv Acknowledgements vii Abbreviations x Abstract xiii Chapter I Introduction 1 Chapter II Meningioma 1 (MN1) is a 1,25-dihydroxyvitamin D3- 44 induced transcription coactivator that promotes osteoblast proliferation, motility, differentiation, and function Chapter III Semaphorin 3B (SEMA3B) is a 1,25- 108 dihydroxyvitamin D3-induced gene in osteoblasts that promotes -
Essential Thrombocythemia Facts No
Essential Thrombocythemia Facts No. 12 in a series providing the latest information for patients, caregivers and healthcare professionals www.LLS.org • Information Specialist: 800.955.4572 Introduction Highlights Essential thrombocythemia (ET) is one of several l Essential thrombocythemia (ET) is one of a related “myeloproliferative neoplasms” (MPNs), a group of closely group of blood cancers known as “myeloproliferative related blood cancers that share several features, notably the neoplasms” (MPNs) in which cells in the bone “clonal” overproduction of one or more blood cell lines. marrow that produce the blood cells develop and All clonal disorders begin with one or more changes function abnormally. (mutations) to the DNA in a single cell; the altered cells in l ET begins with one or more acquired changes the marrow and the blood are the offspring of that one (mutations) to the DNA of a single blood-forming mutant cell. Other MPNs include polycythemia vera and cell. This results in the overproduction of blood cells, myelofibrosis. especially platelets, in the bone marrow. The effects of ET result from uncontrolled blood cell l About half of individuals with ET have a mutation production, notably of platelets. Because the disease arises of the JAK2 (Janus kinase 2) gene. The role that this from a change to an early blood-forming cell that has the mutation plays in the development of the disease, capacity to form red cells, white cells and platelets, any and the potential implications for new treatments, combination of these three cell lines may be affected – and are being investigated. usually each cell line is affected to some degree. -
Semaphorin 3B Is a 1,25-Dihydroxyvitamin D3 -Induced
0888-8809/08/$15.00/0 Molecular Endocrinology 22(6):1370–1381 Printed in U.S.A. Copyright © 2008 by The Endocrine Society doi: 10.1210/me.2007-0363 Semaphorin 3B Is a 1,25-Dihydroxyvitamin D3-Induced Gene in Osteoblasts that Promotes Osteoclastogenesis and Induces Osteopenia in Mice Amelia L. M. Sutton,* Xiaoxue Zhang,* Diane R. Dowd, Yogendra P. Kharode, Barry S. Komm, and Paul N. MacDonald Department of Pharmacology (A.L.M.S., X.Z., D.R.D., P.N.M.), Case Western Reserve University, Cleveland Ohio 44106; and Women’s Heath Research Institute (Y.P.K., B.S.K.), Wyeth Research, Collegeville, Pennsylvania 19426 The vitamin D endocrine system is important for global skeletal homeostasis in intact animals and skeletal homeostasis. 1,25-Dihydroxyvitamin D3 osteoblast function in cell culture. Osteoblast-tar- [1,25(OH)2D3] impacts bone indirectly by promot- geted expression of SEMA3B in mice resulted in ing intestinal absorption of calcium and phosphate reduced bone mineral density and aberrant trabec- and directly by acting on osteoblasts and oste- ular structure compared with nontransgenic litter- oclasts. Despite the direct actions of 1,25(OH)2D3 mates. Histomorphometry studies indicated that in bone, relatively little is known of the mecha- this was likely due to increased osteoclast num- nisms or target genes that are regulated by bers and activity. Indeed, primary osteoblasts ob- 1,25(OH)2D3 in skeletal cells. Here, we identify tained from SEMA3B transgenic mice stimulated semaphorin 3B (SEMA3B) as a 1,25(OH)2D3-stimu- osteoclastogenesis to a greater extent than non- lated gene in osteoblastic cells.